Jaguar Health Inc (NASDAQ: JAGX) is making a run for the top in the market this morning. However, if you’re looking for press releases or SEC filings, you won’t find anything issued by the company. So, what’s the deal? Today, we’ll talk about:
Please Read the update below!
- Why JAGX stock is headed up;
- what we’re seeing from the stock in the market; and
- what we’ll be watching for ahead.
Here’s Why JAGX Stock Is Headed Up
UPDATE: After digging further, we found that the report leading to the gains today was a paid advertisement. While paid advertisements are often used in the right ways, they are sometimes used in pump and dump scemes. Considering that the press release associated with this paid advertisement did not imply that the firm had been paid, there’s a storng chance that this is the case here. Be very careful if you play this run!
As mentioned above, Jaguar Health is having a great day in the market today. However, with no press releases or SEC filings, the question is, why?
The answer is relatively simple. An independent equity research firm, known as Traders News Source, issued a report surrounding the company. The report focused on the pipeline and progress made at JAGX.
In particular, the report centered around Mytesi. The product was developed by the company’s wholly-owned subsidiary Napo Pharmaceuticals. Today, Mytesi is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on atiretroviral therapy.
The equity research firm sees quite a bit of value in JAGX as a result of Mytesi. The lead ingredient in the drug, Crofelemer, is a botanical drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree. The tree is commonly found in the Amazon Rainforest.
According to Traders News Source, Napo has established a sustainable harvest program for the active ingredient. A program that ensures a high degree of quality while maintaining ecological integrity.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Jaguar Health, while the company didn’t release any news of its own, the pipeline review by Traders News Source seems to be exciting investors.
So, it’s not surprising to see that the stock is making a run for the top in the market today. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:14), JAGX is trading at $0.32 per share after a gain of $0.035 per share or 12.70% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on JAGX. In particular, we’re interested in following the story surrounding the company’s and its subsidiary’s continued work to expand sales of Mytesi. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!